Early bactericidal activity of sitafloxacin against pulmonary tuberculosis
Sitafloxacin is a quinolone broad-spectrum antimicrobial agent, and its pharmacologic properties and data demonstrate that sitafloxacin has a potent killing effect against , including drug-resistant strains, which is superior to that of other available quinolones. However, its efficacy in patients w...
Gespeichert in:
| Veröffentlicht in: | Microbiology spectrum 2024-12, p.e0164524 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | e0164524 |
| container_title | Microbiology spectrum |
| container_volume | |
| creator | Nie, Lihui Tong, Jing Wu, Guihui Du, Juan Shang, Yuanyuan Wang, Yufeng Wu, Zhangjun Xu, Yuanhong Ren, Yi Rao, Youyi Pang, Yu Gao, Mengqiu |
| description | Sitafloxacin is a quinolone broad-spectrum antimicrobial agent, and its pharmacologic properties and
data demonstrate that sitafloxacin has a potent killing effect against
, including drug-resistant strains, which is superior to that of other available quinolones. However, its efficacy in patients with primary-sensitive tuberculosis is unclear. This study aims to evaluate the early bactericidal activity (EBA) of sitafloxacin in patients with primary drug-susceptible tuberculosis. In this early bactericidal activity study, 30 patients with primary smear-positive tuberculosis were randomized to the once-daily oral administration of 200 mg sitafloxacin, 500 mg levofloxacin, or 300 mg isoniazid (INH) for 7 days. Sputum for quantitative culture was collected 2 days before the study of drug administration, followed by 16 hours of overnight sputum collected daily for 7 days of monotherapy. Colony-forming units (CFU) of
were counted from the collected overnight sputum on agar plates to calculate the EBA, defined as log
CFU/mL sputum/day. The bactericidal activity was measured by measuring the first 2 days (early bactericidal activity 0-2) and the last 5 days (prolonged early bactericidal properties 2-7) of study drug administration. The EBA 0-2 of INH (0.39 ± 0.22 log
CFU/mL/day) was higher than that of levofloxacin (0.26 ± 0.27 log10CFU/mL/day) and sitafloxacin (0.22 ± 0.25 log
CFU/mL/day), with no statistically significant difference (
= 0.08). EBA 0-2 was similar for the three drugs. INH prolonged early bactericidal activity (2-7) (0.17 ± 0.16 log
CFU/mL/day) was higher than levofloxacin (0.14 ± 0.10 log
CFU/mL/day) and lower than sitafloxacin (0.26 ± 0.31 log
CFU/mL/day), with no statistically significant difference (
= 0.59). The EBA 2-7 of sitafloxacin showed higher activity than INH and levofloxacin. Sitafloxacin exhibits comparable early bactericidal activity and higher extended early bactericidal activity relative to levofloxacin. In addition, this novel fluoroquinolone has a good safety profile. The study data highlights the potential of sitafloxacin in the clinical management of drug-susceptible tuberculosis, as well as drug-resistant tuberculosis.IMPORTANCESitafloxacin is a quinolone broad-spectrum antimicrobial agent, and its pharmacologic properties and
data demonstrate that sitafloxacin has a potent killing effect against
. However, its efficacy in patients with primary-sensitive tuberculosis is unclear. We investigated the early bactericidal activi |
| doi_str_mv | 10.1128/spectrum.01645-24 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146609961</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146609961</sourcerecordid><originalsourceid>FETCH-LOGICAL-a265t-74acc52c2566296238afb1a35d0ef27ae274028f7c974ad68be1af88380878653</originalsourceid><addsrcrecordid>eNp9kEtPwzAQhC0EolXpD-CCcuSS4kfsOEdUlZcqcYGztXFs5MpJih0j-u8JtEWcOO0cZnZnP4QuCV4QQuVN3Bo9hNQuMBEFz2lxgqaUCJ7joipP_-gJmse4wRgTgjnl9BxNWCW4wIRN0dMKgt9lNejBBKddAz4btftwwy7rbRbdANb3n6Bdl8EbuC4O2Tb5tu8g7LIh1Sbo5Pvo4gU6s-CjmR_mDL3erV6WD_n6-f5xebvOgQo-5GUBWnOqKReCVoIyCbYmwHiDjaUlGFoWmEpb6mq0NkLWhoCVkkksSyk4m6Hr_d5t6N-TiYNqXdTGe-hMn6JipBACV5Ugo5XsrTr0MQZj1Ta4diyuCFbfFNWRovqhqGgxZhb7DMSWqk2fQjd-82_g6tAn1a1pfk8cIbMvkpl_bA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146609961</pqid></control><display><type>article</type><title>Early bactericidal activity of sitafloxacin against pulmonary tuberculosis</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Nie, Lihui ; Tong, Jing ; Wu, Guihui ; Du, Juan ; Shang, Yuanyuan ; Wang, Yufeng ; Wu, Zhangjun ; Xu, Yuanhong ; Ren, Yi ; Rao, Youyi ; Pang, Yu ; Gao, Mengqiu</creator><contributor>Sundaramurthy, Varadharajan</contributor><creatorcontrib>Nie, Lihui ; Tong, Jing ; Wu, Guihui ; Du, Juan ; Shang, Yuanyuan ; Wang, Yufeng ; Wu, Zhangjun ; Xu, Yuanhong ; Ren, Yi ; Rao, Youyi ; Pang, Yu ; Gao, Mengqiu ; Sundaramurthy, Varadharajan</creatorcontrib><description>Sitafloxacin is a quinolone broad-spectrum antimicrobial agent, and its pharmacologic properties and
data demonstrate that sitafloxacin has a potent killing effect against
, including drug-resistant strains, which is superior to that of other available quinolones. However, its efficacy in patients with primary-sensitive tuberculosis is unclear. This study aims to evaluate the early bactericidal activity (EBA) of sitafloxacin in patients with primary drug-susceptible tuberculosis. In this early bactericidal activity study, 30 patients with primary smear-positive tuberculosis were randomized to the once-daily oral administration of 200 mg sitafloxacin, 500 mg levofloxacin, or 300 mg isoniazid (INH) for 7 days. Sputum for quantitative culture was collected 2 days before the study of drug administration, followed by 16 hours of overnight sputum collected daily for 7 days of monotherapy. Colony-forming units (CFU) of
were counted from the collected overnight sputum on agar plates to calculate the EBA, defined as log
CFU/mL sputum/day. The bactericidal activity was measured by measuring the first 2 days (early bactericidal activity 0-2) and the last 5 days (prolonged early bactericidal properties 2-7) of study drug administration. The EBA 0-2 of INH (0.39 ± 0.22 log
CFU/mL/day) was higher than that of levofloxacin (0.26 ± 0.27 log10CFU/mL/day) and sitafloxacin (0.22 ± 0.25 log
CFU/mL/day), with no statistically significant difference (
= 0.08). EBA 0-2 was similar for the three drugs. INH prolonged early bactericidal activity (2-7) (0.17 ± 0.16 log
CFU/mL/day) was higher than levofloxacin (0.14 ± 0.10 log
CFU/mL/day) and lower than sitafloxacin (0.26 ± 0.31 log
CFU/mL/day), with no statistically significant difference (
= 0.59). The EBA 2-7 of sitafloxacin showed higher activity than INH and levofloxacin. Sitafloxacin exhibits comparable early bactericidal activity and higher extended early bactericidal activity relative to levofloxacin. In addition, this novel fluoroquinolone has a good safety profile. The study data highlights the potential of sitafloxacin in the clinical management of drug-susceptible tuberculosis, as well as drug-resistant tuberculosis.IMPORTANCESitafloxacin is a quinolone broad-spectrum antimicrobial agent, and its pharmacologic properties and
data demonstrate that sitafloxacin has a potent killing effect against
. However, its efficacy in patients with primary-sensitive tuberculosis is unclear. We investigated the early bactericidal activity of sitafloxacin in primary susceptible tuberculosis. The results showed that sitafloxacin exhibited comparable early bactericidal activity and higher extended early bactericidal activity relative to levofloxacin. In addition, this novel fluoroquinolone has a good safety profile. Our study data highlights the potential of sitafloxacin in the clinical management of drug-susceptible tuberculosis, as well as drug-resistant tuberculosis.</description><identifier>ISSN: 2165-0497</identifier><identifier>EISSN: 2165-0497</identifier><identifier>DOI: 10.1128/spectrum.01645-24</identifier><identifier>PMID: 39656013</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Antimicrobial Chemotherapy ; Research Article</subject><ispartof>Microbiology spectrum, 2024-12, p.e0164524</ispartof><rights>Copyright © 2024 Nie et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-a265t-74acc52c2566296238afb1a35d0ef27ae274028f7c974ad68be1af88380878653</cites><orcidid>0000-0001-6803-9807 ; 0000-0002-4084-780X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39656013$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Sundaramurthy, Varadharajan</contributor><creatorcontrib>Nie, Lihui</creatorcontrib><creatorcontrib>Tong, Jing</creatorcontrib><creatorcontrib>Wu, Guihui</creatorcontrib><creatorcontrib>Du, Juan</creatorcontrib><creatorcontrib>Shang, Yuanyuan</creatorcontrib><creatorcontrib>Wang, Yufeng</creatorcontrib><creatorcontrib>Wu, Zhangjun</creatorcontrib><creatorcontrib>Xu, Yuanhong</creatorcontrib><creatorcontrib>Ren, Yi</creatorcontrib><creatorcontrib>Rao, Youyi</creatorcontrib><creatorcontrib>Pang, Yu</creatorcontrib><creatorcontrib>Gao, Mengqiu</creatorcontrib><title>Early bactericidal activity of sitafloxacin against pulmonary tuberculosis</title><title>Microbiology spectrum</title><addtitle>Spectrum</addtitle><addtitle>Microbiol Spectr</addtitle><description>Sitafloxacin is a quinolone broad-spectrum antimicrobial agent, and its pharmacologic properties and
data demonstrate that sitafloxacin has a potent killing effect against
, including drug-resistant strains, which is superior to that of other available quinolones. However, its efficacy in patients with primary-sensitive tuberculosis is unclear. This study aims to evaluate the early bactericidal activity (EBA) of sitafloxacin in patients with primary drug-susceptible tuberculosis. In this early bactericidal activity study, 30 patients with primary smear-positive tuberculosis were randomized to the once-daily oral administration of 200 mg sitafloxacin, 500 mg levofloxacin, or 300 mg isoniazid (INH) for 7 days. Sputum for quantitative culture was collected 2 days before the study of drug administration, followed by 16 hours of overnight sputum collected daily for 7 days of monotherapy. Colony-forming units (CFU) of
were counted from the collected overnight sputum on agar plates to calculate the EBA, defined as log
CFU/mL sputum/day. The bactericidal activity was measured by measuring the first 2 days (early bactericidal activity 0-2) and the last 5 days (prolonged early bactericidal properties 2-7) of study drug administration. The EBA 0-2 of INH (0.39 ± 0.22 log
CFU/mL/day) was higher than that of levofloxacin (0.26 ± 0.27 log10CFU/mL/day) and sitafloxacin (0.22 ± 0.25 log
CFU/mL/day), with no statistically significant difference (
= 0.08). EBA 0-2 was similar for the three drugs. INH prolonged early bactericidal activity (2-7) (0.17 ± 0.16 log
CFU/mL/day) was higher than levofloxacin (0.14 ± 0.10 log
CFU/mL/day) and lower than sitafloxacin (0.26 ± 0.31 log
CFU/mL/day), with no statistically significant difference (
= 0.59). The EBA 2-7 of sitafloxacin showed higher activity than INH and levofloxacin. Sitafloxacin exhibits comparable early bactericidal activity and higher extended early bactericidal activity relative to levofloxacin. In addition, this novel fluoroquinolone has a good safety profile. The study data highlights the potential of sitafloxacin in the clinical management of drug-susceptible tuberculosis, as well as drug-resistant tuberculosis.IMPORTANCESitafloxacin is a quinolone broad-spectrum antimicrobial agent, and its pharmacologic properties and
data demonstrate that sitafloxacin has a potent killing effect against
. However, its efficacy in patients with primary-sensitive tuberculosis is unclear. We investigated the early bactericidal activity of sitafloxacin in primary susceptible tuberculosis. The results showed that sitafloxacin exhibited comparable early bactericidal activity and higher extended early bactericidal activity relative to levofloxacin. In addition, this novel fluoroquinolone has a good safety profile. Our study data highlights the potential of sitafloxacin in the clinical management of drug-susceptible tuberculosis, as well as drug-resistant tuberculosis.</description><subject>Antimicrobial Chemotherapy</subject><subject>Research Article</subject><issn>2165-0497</issn><issn>2165-0497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kEtPwzAQhC0EolXpD-CCcuSS4kfsOEdUlZcqcYGztXFs5MpJih0j-u8JtEWcOO0cZnZnP4QuCV4QQuVN3Bo9hNQuMBEFz2lxgqaUCJ7joipP_-gJmse4wRgTgjnl9BxNWCW4wIRN0dMKgt9lNejBBKddAz4btftwwy7rbRbdANb3n6Bdl8EbuC4O2Tb5tu8g7LIh1Sbo5Pvo4gU6s-CjmR_mDL3erV6WD_n6-f5xebvOgQo-5GUBWnOqKReCVoIyCbYmwHiDjaUlGFoWmEpb6mq0NkLWhoCVkkksSyk4m6Hr_d5t6N-TiYNqXdTGe-hMn6JipBACV5Ugo5XsrTr0MQZj1Ta4diyuCFbfFNWRovqhqGgxZhb7DMSWqk2fQjd-82_g6tAn1a1pfk8cIbMvkpl_bA</recordid><startdate>20241210</startdate><enddate>20241210</enddate><creator>Nie, Lihui</creator><creator>Tong, Jing</creator><creator>Wu, Guihui</creator><creator>Du, Juan</creator><creator>Shang, Yuanyuan</creator><creator>Wang, Yufeng</creator><creator>Wu, Zhangjun</creator><creator>Xu, Yuanhong</creator><creator>Ren, Yi</creator><creator>Rao, Youyi</creator><creator>Pang, Yu</creator><creator>Gao, Mengqiu</creator><general>American Society for Microbiology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6803-9807</orcidid><orcidid>https://orcid.org/0000-0002-4084-780X</orcidid></search><sort><creationdate>20241210</creationdate><title>Early bactericidal activity of sitafloxacin against pulmonary tuberculosis</title><author>Nie, Lihui ; Tong, Jing ; Wu, Guihui ; Du, Juan ; Shang, Yuanyuan ; Wang, Yufeng ; Wu, Zhangjun ; Xu, Yuanhong ; Ren, Yi ; Rao, Youyi ; Pang, Yu ; Gao, Mengqiu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a265t-74acc52c2566296238afb1a35d0ef27ae274028f7c974ad68be1af88380878653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antimicrobial Chemotherapy</topic><topic>Research Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nie, Lihui</creatorcontrib><creatorcontrib>Tong, Jing</creatorcontrib><creatorcontrib>Wu, Guihui</creatorcontrib><creatorcontrib>Du, Juan</creatorcontrib><creatorcontrib>Shang, Yuanyuan</creatorcontrib><creatorcontrib>Wang, Yufeng</creatorcontrib><creatorcontrib>Wu, Zhangjun</creatorcontrib><creatorcontrib>Xu, Yuanhong</creatorcontrib><creatorcontrib>Ren, Yi</creatorcontrib><creatorcontrib>Rao, Youyi</creatorcontrib><creatorcontrib>Pang, Yu</creatorcontrib><creatorcontrib>Gao, Mengqiu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Microbiology spectrum</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nie, Lihui</au><au>Tong, Jing</au><au>Wu, Guihui</au><au>Du, Juan</au><au>Shang, Yuanyuan</au><au>Wang, Yufeng</au><au>Wu, Zhangjun</au><au>Xu, Yuanhong</au><au>Ren, Yi</au><au>Rao, Youyi</au><au>Pang, Yu</au><au>Gao, Mengqiu</au><au>Sundaramurthy, Varadharajan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early bactericidal activity of sitafloxacin against pulmonary tuberculosis</atitle><jtitle>Microbiology spectrum</jtitle><stitle>Spectrum</stitle><addtitle>Microbiol Spectr</addtitle><date>2024-12-10</date><risdate>2024</risdate><spage>e0164524</spage><pages>e0164524-</pages><issn>2165-0497</issn><eissn>2165-0497</eissn><abstract>Sitafloxacin is a quinolone broad-spectrum antimicrobial agent, and its pharmacologic properties and
data demonstrate that sitafloxacin has a potent killing effect against
, including drug-resistant strains, which is superior to that of other available quinolones. However, its efficacy in patients with primary-sensitive tuberculosis is unclear. This study aims to evaluate the early bactericidal activity (EBA) of sitafloxacin in patients with primary drug-susceptible tuberculosis. In this early bactericidal activity study, 30 patients with primary smear-positive tuberculosis were randomized to the once-daily oral administration of 200 mg sitafloxacin, 500 mg levofloxacin, or 300 mg isoniazid (INH) for 7 days. Sputum for quantitative culture was collected 2 days before the study of drug administration, followed by 16 hours of overnight sputum collected daily for 7 days of monotherapy. Colony-forming units (CFU) of
were counted from the collected overnight sputum on agar plates to calculate the EBA, defined as log
CFU/mL sputum/day. The bactericidal activity was measured by measuring the first 2 days (early bactericidal activity 0-2) and the last 5 days (prolonged early bactericidal properties 2-7) of study drug administration. The EBA 0-2 of INH (0.39 ± 0.22 log
CFU/mL/day) was higher than that of levofloxacin (0.26 ± 0.27 log10CFU/mL/day) and sitafloxacin (0.22 ± 0.25 log
CFU/mL/day), with no statistically significant difference (
= 0.08). EBA 0-2 was similar for the three drugs. INH prolonged early bactericidal activity (2-7) (0.17 ± 0.16 log
CFU/mL/day) was higher than levofloxacin (0.14 ± 0.10 log
CFU/mL/day) and lower than sitafloxacin (0.26 ± 0.31 log
CFU/mL/day), with no statistically significant difference (
= 0.59). The EBA 2-7 of sitafloxacin showed higher activity than INH and levofloxacin. Sitafloxacin exhibits comparable early bactericidal activity and higher extended early bactericidal activity relative to levofloxacin. In addition, this novel fluoroquinolone has a good safety profile. The study data highlights the potential of sitafloxacin in the clinical management of drug-susceptible tuberculosis, as well as drug-resistant tuberculosis.IMPORTANCESitafloxacin is a quinolone broad-spectrum antimicrobial agent, and its pharmacologic properties and
data demonstrate that sitafloxacin has a potent killing effect against
. However, its efficacy in patients with primary-sensitive tuberculosis is unclear. We investigated the early bactericidal activity of sitafloxacin in primary susceptible tuberculosis. The results showed that sitafloxacin exhibited comparable early bactericidal activity and higher extended early bactericidal activity relative to levofloxacin. In addition, this novel fluoroquinolone has a good safety profile. Our study data highlights the potential of sitafloxacin in the clinical management of drug-susceptible tuberculosis, as well as drug-resistant tuberculosis.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>39656013</pmid><doi>10.1128/spectrum.01645-24</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6803-9807</orcidid><orcidid>https://orcid.org/0000-0002-4084-780X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2165-0497 |
| ispartof | Microbiology spectrum, 2024-12, p.e0164524 |
| issn | 2165-0497 2165-0497 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3146609961 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Antimicrobial Chemotherapy Research Article |
| title | Early bactericidal activity of sitafloxacin against pulmonary tuberculosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A04%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20bactericidal%20activity%20of%20sitafloxacin%20against%20pulmonary%20tuberculosis&rft.jtitle=Microbiology%20spectrum&rft.au=Nie,%20Lihui&rft.date=2024-12-10&rft.spage=e0164524&rft.pages=e0164524-&rft.issn=2165-0497&rft.eissn=2165-0497&rft_id=info:doi/10.1128/spectrum.01645-24&rft_dat=%3Cproquest_cross%3E3146609961%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3146609961&rft_id=info:pmid/39656013&rfr_iscdi=true |